课题基金 / 基金详情

Impact of Anthrax Toxin on Embryonic Development

Impact of Anthrax Toxin on Embryonic Development
炭疽毒素对胚胎发育的影响
批准号:
6672327
负责人:
Jimmy D. Ballard
金额:
$29.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2004-08-14

项目摘要

项目成果

Jimmy D. Ballard的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Bacillus anthracis lethal toxin and edema toxin modify the physiology of cells by disrupting MAPKK signaling pathways and causing accumulation of cAMP respectively. Both MAPKK signaling and cAMP are important regulators of development and exposure of embryos to anthrax toxin could lead to defects. In recent DNA array studies we have found that Wnt signalling may also be disrupted by lethal toxin. Wnt signaling is a major part of development and aberrations in this pathway could also lead to defects in the developing embryo. In light of these observations we carried out pilot experiments on zebrafish embryos and found noticeable defects after treatment with anthrax toxin. These results strongly suggest a better understanding of anthrax toxin's impact on development is needed. In the case of a bioterrorist disseminating B. anthracis spores over a populated area, at least 1.5% of the human population will be pregnant and embryos could be exposed to the toxin. Therefore, in order to better understand the impact of anthrax toxin on embryonic development, we will address two specific aims. Specific Aim 1. We will determine the impact lethal toxin and edema toxin have on zebrafish embryo development. Specific Aim 2. We will determine the impact inactive anthrax toxin mutants have on zebrafish embryo development. Specific aim 2 will address the possibility that vaccine and therapeutic candidates might cause developmental defects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oklahoma C. difficile U19 Challenge Core
Enhancing C. difficile vaccination in the context of TcdB-mediated immunosuppression.
Oklahoma CMP&I Administrative Core
Oklahoma Center for Microbial Pathogenesis and Immunity
海外基金